Guardant Health, Inc. (GH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 287 | 374 | 450 | 564 | 739 | 982 | 1,183 | 1,358 |
| Operating profit | $m | -437 | -470 | ||||||
| Net profit | $m | -254 | -406 | -655 | -479 | -436 | -416 | -453 | -393 |
| EPS reported | $ | -3.32 | -3.49 | ||||||
| Operating cashflow per share | $ | -1.47 | -1.40 | ||||||
| Capex per share | $ | 0.39 | 0.42 | ||||||
| FCF per share | $ | -1.86 | -1.82 | ||||||
| Free cash flow | $m | -233 | -241 | ||||||
| Net debt | $m | 302 | 477 | ||||||
| Book value equity | $m | -99 | -223 | ||||||
| Book value per share | $ | -0.79 | -1.69 | ||||||
| Number of shares | m | 125.37 | 132.07 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -128.95 | -57.46 | ||||||
| P/S LTM | x | 13.04 | 10.82 | ||||||
| P/FCF LTM | x | -54.94 | -53.20 | ||||||
| EV/EBITDA LTM | x | -37.81 | -34.38 | ||||||
| EV/Sales LTM | x | 14.40 | 18.38 | ||||||
| Earnings Yield LTM | % | -3.25% | -2.18% | ||||||
| FCF Yield | % | -1.82% | -1.88% | ||||||
| Quality | |||||||||
| ROE | % | +419.18% | +211.46% | ||||||
| ROIC | % | -25.07% | -29.30% | ||||||
| Operating margin | % | -44.53% | -39.75% | ||||||
| Gross margin | % | +64.46% | +65.01% | ||||||
| FCF/Sales | % | -23.73% | -20.35% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +32.88% | +60.09% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.14 | -0.14 | ||||||
| Net Debt/EBITDA | x | -3.56 | -1.57 | ||||||
| EBIT/Net interest | x | -112.20 | -97.65 | ||||||
| Net debt/market cap | % | +11.74% | +7.12% | ||||||
| Net debt/Equity | x | -3.05 | -2.14 | ||||||
| Gross debt/equity | x | -17.22 | -7.61 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free